F 527
Alternative Names: F-527Latest Information Update: 25 Apr 2022
At a glance
- Originator Shandong New Time Pharmaceutical Co LTD
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lymphoma
Most Recent Events
- 29 Mar 2022 NP created based on NCT05293028
- 23 Mar 2022 Preclinical trials in Lymphoma in China before March 2022 (NCT05293028).
- 23 Mar 2022 Shandong New Time Pharmaceutical plans a phase I trial for Lymphoma (Second-line therapy or greater) in China in May 2022 (NCT05293028)